Genmab, Pfizer’s tisotumab vedotin takes a leap towards EU approval for cervical cancer

In a significant development for cervical cancer treatment, Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) have announced the European Medicines Agency's (EMA) validation ... Read More